Atlas Trials

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Clinical trial NCT06771674 · COMPLETED

Trial details

NCT number
NCT06771674
Sponsor
Hookipa Biotech GmbH
Status
COMPLETED
Study type
OBSERVATIONAL
Oropharyngeal Squamous Cell Carcinoma
Start date
2024-06-05
Primary completion
2025-02-28
Enrollment
662

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.